Aktis Oncology, Inc.
NASDAQ:AKTSBiotechnology
+$0.11 today
- Market cap
- $865.32M
- Beta
- 1.10
- P/E (TTM)
- -28.7
- EPS (TTM)
- -$0.82
Volume 0.44M
Average 0.33M
AKTS Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Aktis Oncology, Inc.NASDAQ: AKTS
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables of -$1.11M in Q1 FY2026
Q1 FY2026 accounts receivables was -$1.11M.
Context
- Accounts receivables amounted to 15.9% of revenue in FY2025, down 42.0 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 1.03M USD
- Year-over-year change
- +220.1%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.03M | +220.1% |
| FY2024 | 2024-12-31 | (861K) | -235.0% |
| FY2023 | 2023-12-31 | (257K) | — |
| FY2022 | 2022-12-31 | 0 | — |
Accounts Receivables vs competitors
How AKTS compares with its peers on the latest reported figures
- AKTS's FY2025 accounts receivables of $1.03M is the 3rd largest of the 6 companies compared; the peer median is $0.
- Its year-over-year change of +220.1% is the highest of 4, against a peer median of +103.5%.
- Accounts receivables amounts to 15.9% of revenue for AKTS, versus a peer median of 4.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $16.59M | +211.8% | -40.8% | 4.3% | |
| LTM Mar 2026 | $3.41M | -86.4% | — | 5.4% | |
| FY2025 | $1.03M | +220.1% | — | 15.9% | |
| LTM Mar 2026 | $117K | +103.5% | -41.7% | 0.1% | |
| LTM Sep 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding AKTS) | $0 | +103.5% | -41.3% | 4.3% | |
Competitors are the stored peer set for AKTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (17.93M) | (28.64M) | (43.98M) | (63.73M) |
| Depreciation & Amortization | 445K | 1.12M | 1.58M | 2.33M |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 698K | 1.48M | 2.26M | 5.13M |
| Change in Working Capital | (1.14M) | (15K) | 58.98M | (3.23M) |
| Accounts Receivables | 0 | (257K) | (861K) | 1.03M |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | (1K) | 659K | 360K | (44K) |
| Other Working Capital | (1.14M) | (417K) | 59.48M | (4.22M) |
| Other Non-Cash Items | (200K) | (3.95M) | (4.07M) | (4.62M) |
| Operating Cash Flow | (18.13M) | (30M) | 14.76M | (64.13M) |
| Capital Expenditures | (2.31M) | (3.76M) | (2.86M) | (9.58M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (145.81M) | (288.4M) | (193.87M) |
| Sales of Investments | 0 | 80.69M | 100.86M | 269.42M |
| Other Investing Activities | 0 | 57K | 0 | 0 |
| Investing Cash Flow | (2.31M) | (68.83M) | (190.4M) | 65.96M |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 336K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | (151K) | 0 | (1.72M) | (1.55M) |
| Financing Cash Flow | 119.98M | 0 | 183.28M | (1.21M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | 99.55M | (98.83M) | 7.65M | 625K |
| Free Cash Flow | (20.43M) | (33.77M) | 11.9M | (73.71M) |
Aktis Oncology, Inc.
NASDAQ:AKTS
Intrinsic Alpha fair value
Locked
Current Price
$16.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.